ECSP21043491A - Derivados de pirimidona como agentes citotóxicos selectivos contra células infectadas por vih - Google Patents
Derivados de pirimidona como agentes citotóxicos selectivos contra células infectadas por vihInfo
- Publication number
- ECSP21043491A ECSP21043491A ECSENADI202143491A ECDI202143491A ECSP21043491A EC SP21043491 A ECSP21043491 A EC SP21043491A EC SENADI202143491 A ECSENADI202143491 A EC SENADI202143491A EC DI202143491 A ECDI202143491 A EC DI202143491A EC SP21043491 A ECSP21043491 A EC SP21043491A
- Authority
- EC
- Ecuador
- Prior art keywords
- pyrimidone derivatives
- infected cells
- cytotoxic agents
- against hiv
- agents against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación se refiere a derivados de pirimidona de la Fórmula I, que consta en el resumen de la memoría técnica, y su uso para inactivar selectivamente células que expresan GAG-POL infectadas por VIH sin citotoxicidad concomitante con respecto a células indiferenciadas para VIH, y para el tratamiento o la profilaxis de infección por VIH, o para el tratamiento, profilaxis, o retraso en la aparición o la progresión de SIDA o complejo relacionado con el sida (ARC).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781356P | 2018-12-18 | 2018-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21043491A true ECSP21043491A (es) | 2021-07-30 |
Family
ID=69411500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202143491A ECSP21043491A (es) | 2018-12-18 | 2021-06-15 | Derivados de pirimidona como agentes citotóxicos selectivos contra células infectadas por vih |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US12258329B2 (es) |
| EP (1) | EP3898595B1 (es) |
| JP (1) | JP7045528B2 (es) |
| KR (1) | KR102645602B1 (es) |
| CN (1) | CN113423695A (es) |
| AR (1) | AR119126A1 (es) |
| AU (1) | AU2019402998B2 (es) |
| BR (1) | BR112021011733A8 (es) |
| CA (1) | CA3122571C (es) |
| CL (2) | CL2021001514A1 (es) |
| CO (1) | CO2021007667A2 (es) |
| CR (1) | CR20210317A (es) |
| DO (1) | DOP2021000129A (es) |
| EA (1) | EA202191711A1 (es) |
| EC (1) | ECSP21043491A (es) |
| IL (1) | IL283821A (es) |
| JO (1) | JOP20210149A1 (es) |
| MA (1) | MA54549A (es) |
| MX (1) | MX2021007382A (es) |
| NI (1) | NI202100048A (es) |
| PE (1) | PE20211704A1 (es) |
| PH (1) | PH12021551408A1 (es) |
| SG (1) | SG11202106310YA (es) |
| TW (1) | TW202122384A (es) |
| WO (1) | WO2020131597A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20211704A1 (es) | 2018-12-18 | 2021-09-01 | Merck Sharp & Dohme | Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih |
| US20220242847A1 (en) * | 2019-05-22 | 2022-08-04 | Merck Sharp & Dohme Corp. | Pyridinone derivatives as selective cytotoxic agents against hiv infected cells |
| US12378229B2 (en) | 2021-02-02 | 2025-08-05 | Liminal Biosciences Limited | GPR84 antagonists and uses thereof |
| US12133620B2 (en) | 2022-02-11 | 2024-11-05 | Whirlpool Corporation | Dishwasher with direct water supply |
| CN116217493A (zh) * | 2023-02-07 | 2023-06-06 | 郑州猫眼农业科技有限公司 | 一种4,6-二氯-2-甲基-5-嘧啶甲醛的制备方法 |
| WO2025193566A1 (en) * | 2024-03-15 | 2025-09-18 | Merck Sharp & Dohme Llc | N-oxide derivatives as selective cytotoxic agents |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2000129671A (ru) * | 1998-04-27 | 2004-02-20 | Сантр Насьональ Де Ля Решерш Сьентифик (Fr) | Производные 3-(амино- или аминоалкил) пиридинона и их применение для лечения болезней, связанных с ВИЧ |
| CN100469769C (zh) | 2003-03-24 | 2009-03-18 | 弗·哈夫曼-拉罗切有限公司 | 作为逆转录酶抑制剂的苄基-哒嗪酮 |
| US7166738B2 (en) | 2004-04-23 | 2007-01-23 | Roche Palo Alto Llc | Non-nucleoside reverse transcriptase inhibitors |
| TW200831085A (en) | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
| JP5167350B2 (ja) | 2007-05-30 | 2013-03-21 | エフ．ホフマン−ラ ロシュ アーゲー | 非ヌクレオシド系逆転写酵素阻害剤 |
| KR20100088142A (ko) | 2007-11-20 | 2010-08-06 | 머크 샤프 앤드 돔 코포레이션 | 비-뉴클레오사이드 역전사효소 억제제 |
| HUE025336T2 (en) | 2010-03-30 | 2016-03-29 | Merck Canada Inc | Non-nucleoside reverse transcriptase inhibitors |
| JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| PL3125894T3 (pl) * | 2014-04-01 | 2021-02-08 | Merck Sharp & Dohme Corp. | Proleki inhibitorów odwrotnej transkryptazy hiv |
| EP3669876A1 (en) | 2018-12-18 | 2020-06-24 | Aelis Farma | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
| PE20211704A1 (es) | 2018-12-18 | 2021-09-01 | Merck Sharp & Dohme | Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih |
-
2019
- 2019-12-13 PE PE2021000891A patent/PE20211704A1/es unknown
- 2019-12-13 EA EA202191711A patent/EA202191711A1/ru unknown
- 2019-12-13 MX MX2021007382A patent/MX2021007382A/es unknown
- 2019-12-13 PH PH1/2021/551408A patent/PH12021551408A1/en unknown
- 2019-12-13 SG SG11202106310YA patent/SG11202106310YA/en unknown
- 2019-12-13 WO PCT/US2019/066125 patent/WO2020131597A1/en not_active Ceased
- 2019-12-13 US US17/413,882 patent/US12258329B2/en active Active
- 2019-12-13 CR CR20210317A patent/CR20210317A/es unknown
- 2019-12-13 KR KR1020217022074A patent/KR102645602B1/ko active Active
- 2019-12-13 CN CN201980092427.XA patent/CN113423695A/zh active Pending
- 2019-12-13 AU AU2019402998A patent/AU2019402998B2/en active Active
- 2019-12-13 EP EP19845846.5A patent/EP3898595B1/en active Active
- 2019-12-13 JP JP2021534709A patent/JP7045528B2/ja active Active
- 2019-12-13 JO JOP/2021/0149A patent/JOP20210149A1/ar unknown
- 2019-12-13 CA CA3122571A patent/CA3122571C/en active Active
- 2019-12-13 BR BR112021011733A patent/BR112021011733A8/pt unknown
- 2019-12-13 MA MA054549A patent/MA54549A/fr unknown
-
2020
- 2020-05-20 TW TW109116741A patent/TW202122384A/zh unknown
- 2020-06-09 AR ARP200101624A patent/AR119126A1/es not_active Application Discontinuation
-
2021
- 2021-06-08 IL IL283821A patent/IL283821A/en unknown
- 2021-06-09 CL CL2021001514A patent/CL2021001514A1/es unknown
- 2021-06-11 CO CONC2021/0007667A patent/CO2021007667A2/es unknown
- 2021-06-14 NI NI202100048A patent/NI202100048A/es unknown
- 2021-06-15 EC ECSENADI202143491A patent/ECSP21043491A/es unknown
- 2021-06-18 DO DO2021000129A patent/DOP2021000129A/es unknown
-
2022
- 2022-03-17 CL CL2022000659A patent/CL2022000659A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12258329B2 (en) | 2025-03-25 |
| US20220064147A1 (en) | 2022-03-03 |
| CL2021001514A1 (es) | 2021-11-26 |
| CO2021007667A2 (es) | 2021-07-19 |
| SG11202106310YA (en) | 2021-07-29 |
| AU2019402998B2 (en) | 2022-12-15 |
| KR102645602B1 (ko) | 2024-03-07 |
| KR20210104796A (ko) | 2021-08-25 |
| CA3122571A1 (en) | 2020-06-25 |
| JP2022508380A (ja) | 2022-01-19 |
| EA202191711A1 (ru) | 2021-10-04 |
| PH12021551408A1 (en) | 2022-05-16 |
| BR112021011733A2 (pt) | 2021-08-31 |
| PE20211704A1 (es) | 2021-09-01 |
| DOP2021000129A (es) | 2021-08-15 |
| CR20210317A (es) | 2021-07-14 |
| BR112021011733A8 (pt) | 2023-04-18 |
| TW202122384A (zh) | 2021-06-16 |
| CA3122571C (en) | 2023-08-01 |
| EP3898595A1 (en) | 2021-10-27 |
| NI202100048A (es) | 2021-08-09 |
| JP7045528B2 (ja) | 2022-03-31 |
| AR119126A1 (es) | 2021-11-24 |
| AU2019402998A1 (en) | 2021-06-24 |
| CL2022000659A1 (es) | 2022-10-28 |
| CN113423695A (zh) | 2021-09-21 |
| MA54549A (fr) | 2022-03-30 |
| WO2020131597A1 (en) | 2020-06-25 |
| IL283821A (en) | 2021-07-29 |
| MX2021007382A (es) | 2021-07-15 |
| JOP20210149A1 (ar) | 2023-01-30 |
| EP3898595B1 (en) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21043491A (es) | Derivados de pirimidona como agentes citotóxicos selectivos contra células infectadas por vih | |
| AR130699A2 (es) | Inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4 | |
| MX2019007262A (es) | Compuestos antivirales de bencilamina fosfodiamida. | |
| CA2998646C (en) | 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof | |
| UY37710A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| MX2019007585A (es) | Profarmacos de ester alifatico antiviricos de tenofovir. | |
| BR112023003535A2 (pt) | Derivados de dihidroquinazolin-2-ona como agentes citotóxicos seletivos úteis no tratamento do hiv | |
| CU24525B1 (es) | Derivado de quinoleína para tratar y prevenir infecciones virales | |
| DOP2018000183A (es) | Compuesto útil para el tratamiento y la profilaxis de vih y sida y sus usos | |
| CL2008001537A1 (es) | Compuestos heterociclo derivados de 1h-pirimidin-2,4-diona, dihidro-pirimidin-2,4-diona e imidazol-2,4-diona, inhibidores no nucleosidos de la transcriptasa inversa (nnrti) del vih-1; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por vih, sida o arc. | |
| MX2021014247A (es) | Derivados piridinona como agentes citotoxicos selectivos contra celulas infectadas con virus de inmunodeficiencia humana (vih). | |
| DOP2026000001A (es) | Derivados de tetrahidroquinazolina como agentes citotóxicos selectivos | |
| AR123347A1 (es) | Derivados de tetrahidroquinazolina como agentes citotóxicos selectivos |